Immatics (NASDAQ:IMTX – Get Free Report)‘s stock had its “overweight” rating reaffirmed by equities research analysts at Cantor Fitzgerald in a report released on Thursday, Benzinga reports.
Separately, Mizuho increased their price objective on shares of Immatics from $14.00 to $16.00 and gave the stock a “buy” rating in a report on Thursday, May 16th.
Read Our Latest Analysis on IMTX
Immatics Stock Down 0.5 %
Immatics (NASDAQ:IMTX – Get Free Report) last issued its earnings results on Tuesday, August 13th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.17. Immatics had a negative net margin of 103.99% and a negative return on equity of 23.34%. The company had revenue of $20.19 million for the quarter, compared to analysts’ expectations of $12.36 million. Analysts predict that Immatics will post -1.03 earnings per share for the current fiscal year.
Institutional Trading of Immatics
A number of large investors have recently modified their holdings of the company. Jump Financial LLC increased its stake in Immatics by 19.8% during the 4th quarter. Jump Financial LLC now owns 48,484 shares of the company’s stock valued at $511,000 after buying an additional 8,014 shares during the period. Trexquant Investment LP increased its stake in Immatics by 4.2% during the 4th quarter. Trexquant Investment LP now owns 44,773 shares of the company’s stock valued at $471,000 after buying an additional 1,801 shares during the period. TD Asset Management Inc increased its stake in Immatics by 14.9% during the 4th quarter. TD Asset Management Inc now owns 227,118 shares of the company’s stock valued at $2,392,000 after buying an additional 29,400 shares during the period. RTW Investments LP increased its stake in Immatics by 75.7% during the 4th quarter. RTW Investments LP now owns 1,484,911 shares of the company’s stock valued at $15,636,000 after buying an additional 639,911 shares during the period. Finally, Vestal Point Capital LP acquired a new position in Immatics during the 4th quarter valued at about $22,113,000. Institutional investors and hedge funds own 64.41% of the company’s stock.
About Immatics
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Read More
- Five stocks we like better than Immatics
- What is Put Option Volume?
- Recession or Not, These 3 Stocks Are Winners
- How to Read Stock Charts for Beginners
- Why NVIDIA Is More of a Screaming Buy Than Ever
- What does consumer price index measure?
- Don’t Miss These 3 Stocks Set to Defy Expectations in September
Receive News & Ratings for Immatics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immatics and related companies with MarketBeat.com's FREE daily email newsletter.